Fig 3.
Estimates of (A) progression-free survival and (B) overall survival for each treatment arm, including the cumulative number of events, the number of patients at risk, and a summary of hazard ratios; P values were adjusted for extent of residual disease and participating cooperative group. Median progression-free survival rates varied from 15.4 to 16.4 months, and median overall survival rates varied from 39.6 to 44.2 months. CP, carboplatin and paclitaxel; CPG, carboplatin, paclitaxel, and gemcitabine; CPD, carboplatin, paclitaxel, and doxorubicin; CT-CP, carboplatin plus topotecan, then carboplatin plus paclitaxel; CG-CP, carboplatin plus gemcitabine, then carboplatin plus paclitaxel.